AUTL Autolus Therapeutics plc

11.55
+0.14  (+1%)
Previous Close 11.41
Open 11.41
Price To Book 2.1
Market Cap 603,463,615
Shares 52,247,932
Volume 76,791
Short Ratio
Av. Daily Volume 139,035
Stock charts supplied by TradingView

NewsSee all news

  1. Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020

    LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual

  2. Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

    – Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held Monday, June 15,

  3. Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

    - Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30 am EDT / 1:30 pm BST

  4. Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress

    - Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing

  5. Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7

    LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data due 4Q 2020.
AUTO4
T-cell lymphoma
Phase 2 update at ASCO May 29, 2020.
AUTO3 - (ALEXANDER) (ASCO)
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1 data presented at ASH December 8, 2019.
AUTO2
Relapsed or refractory multiple myeloma
Phase 1 update at EHA June 2020.
AUTO1 (EHA)
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Phase 1 data presented at ASH December 2019.
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia
Phase 1/2 trial to be initiated 2H 2020.
AUTO6
Neuroblastoma

Latest News

  1. Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020

    LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual

  2. Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

    – Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held Monday, June 15,

  3. Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

    - Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30 am EDT / 1:30 pm BST

  4. Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress

    - Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing

  5. Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7

    LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

  6. Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia

    LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer,

  7. Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress

    - Conference call to be held on March 3, 2020 at 8:30 am EST/1:30 pm GMT - LONDON, March 03, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing

  8. Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference

    LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian

  9. Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3

    LONDON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

  10. Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

    - Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab Data presented at EHA-EBMT 2nd European CAR T Cell

  11. Autolus Announces Closing of Public Offering

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its

  12. Autolus' Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that the Company's Founder

  13. Autolus Announces Pricing of Public Offering

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an

  14. Autolus Announces Proposed Public Offering in the United States

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced

  15. Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference

    LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38th Annual J.P.

  16. Autolus Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian

  17. Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

    Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL patients dosed with

  18. Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

    AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome   Data presented at 61st American Society of Hematology Annual Meeting form basis for advancement

  19. Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting

    LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review

  20. Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  21. Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

    LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc.,

  22. Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  23. Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

  24. Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

    LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  25. Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  26. Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  27. Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7

    LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

  28. Autolus Announces Changes to Executive Leadership Team

    LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced changes to the

  29. Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical

  30. Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

    Findings from Phase I CARPALL Trial Demonstrate that Autolus' Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a

  31. Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

    LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will